NEWS - Porosome Therapeutics, Inc.

Porosome Therapeutics, Inc. Academic Chairman Prof. Bhanu P. Jena recognized with the 2024 “Lipid Science Prize”

Porosome Therapeutics Inc., CSO presented at the recent (April 4-7, 2024) American Physiological Society Meetings in Long Beach, CA, studies on porosome reconstitution therapy that overcomes Cystic Fibrosis (CF) both in human bronchial epithelial cells and in CF mice.

Discovery Underlying Porosome Therapeutics, Inc. Continues to Receive Global Recognition

A Patient-Centric Approach Built On The Porosome

Cystic Fibrosis Rescued by Reprogramming the Cell’s Secretory Machinery

Joe Golemme, CFO of Porosome Therapeutics, Inc., invited to participate in the J.P. Morgan 42nd Annual Healthcare Conference 2024 (January 8-11th, 2024) in San Francisco, CA, USA.

Porosome Therapeutic Inc.’s, first therapeutic approach for cystic fibrosis, has just been published as a preprint

Porosome Therapeutics Announces Groundbreaking Approach to Advance Diabetes Treatment

Editorial on the pioneering discovery of the porosome nearly 30-years ago and its current application in the development of novel therapeutics for the treatment and cure of a wide range of debilitating diseases, is published in the Discoveries Journal

Porosome Therapeutics, Inc., Chairman, Prof. Dr. Bhanu P. Jena and Chairman of the Scientific Advisory Board, Prof. Dr. Joachim Frank have been invited to participate at the Nobel Prize Dialogue being held in Seoul, South Korea on September 24th 2023.

Porosome Therapeutics, Inc. Files Comprehensive Patent for New Generation of Treatments for Cystic Fibrosis and Other Diseases

Porosome Therapeutics is the new name of Viron.